STOCK TITAN

Destiny Meda Tec Financials

DSNY
Source SEC Filings (10-K/10-Q) Data as of May 31, 2026 Currency USD FYE August

This page shows Destiny Meda Tec (DSNY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DSNY FY2025

High-gross-margin economics were overwhelmed as expense growth outpaced revenue, pushing a still-cash-generative business into accounting losses.

By FY2025, gross margin stayed above 84.0% even as operating margin fell to -14.7%, which points to a heavier cost structure rather than weaker delivery economics. The fact that operating cash flow remained positive at $65K while net income was -$638K shows the income statement absorbed large non-cash charges, so the reported loss overstated the immediate cash strain.

The business still looks balance-sheet conservative: cash ended at $1.1M against only $544K of liabilities, so a bad earnings year did not force the company into debt-dependent financing. That matters because the pressure is coming from operations, not from a stretched capital structure.

Working capital became less friendly in FY2025, with receivables rising to $863K on revenue of $4.5M, meaning more of each sale was left uncollected at year-end. Since capital spending was only $29K, the squeeze on free cash flow came more from slower cash collection and higher operating spend than from a heavy reinvestment program.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score pending refresh

We are recalculating Destiny Meda Tec's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Safe
6.13

Destiny Meda Tec scores 6.13, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($6.7M) relative to total liabilities ($544K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
4/8

Destiny Meda Tec passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed
-0.10x

For every $1 of reported earnings, Destiny Meda Tec generates $-0.10 in operating cash flow ($65K OCF vs -$638K net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$4.5M
YoY+2.3%
5Y CAGR+3.4%
10Y CAGR+3.1%

Destiny Meda Tec generated $4.5M in revenue in fiscal year 2025. This represents an increase of 2.3% from the prior year.

EBITDA
$171K
YoY-67.8%
5Y CAGR-9.5%

Destiny Meda Tec's EBITDA was $171K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 67.8% from the prior year.

Net Income
-$638K
YoY-670.8%

Destiny Meda Tec reported -$638K in net income in fiscal year 2025. This represents a decrease of 670.8% from the prior year.

EPS (Diluted)
$-0.07
YoY-800.0%

Destiny Meda Tec earned $-0.07 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 800.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow
$36K
YoY-91.4%
5Y CAGR-29.6%

Destiny Meda Tec generated $36K in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 91.4% from the prior year.

Cash & Debt
$1.1M
YoY-24.5%
5Y CAGR-9.5%
10Y CAGR+11.2%

Destiny Meda Tec held $1.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
10M
YoY+0.0%
5Y CAGR-1.6%

Destiny Meda Tec had 10M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin
84.8%
YoY-1.4pp
5Y CAGR-6.8pp

Destiny Meda Tec's gross margin was 84.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.4 percentage points from the prior year.

Operating Margin
-14.7%
YoY-16.0pp
5Y CAGR-18.4pp
10Y CAGR+9.3pp

Destiny Meda Tec's operating margin was -14.7% in fiscal year 2025, reflecting core business profitability. This is down 16.0 percentage points from the prior year.

Net Margin
-14.1%
YoY-16.6pp
5Y CAGR-18.5pp
10Y CAGR+33.9pp

Destiny Meda Tec's net profit margin was -14.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 16.6 percentage points from the prior year.

Return on Equity
-26.3%
YoY-29.9pp
5Y CAGR-32.3pp
10Y CAGR+118.5pp

Destiny Meda Tec's ROE was -26.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 29.9 percentage points from the prior year.

Capital Allocation

R&D Spending
$1.8M
YoY+16.5%
5Y CAGR+5.7%
10Y CAGR+2.5%

Destiny Meda Tec invested $1.8M in research and development in fiscal year 2025. This represents an increase of 16.5% from the prior year.

Share Buybacks
$0
YoY-100.0%

Destiny Meda Tec spent $0 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.

Capital Expenditures
$29K
YoY+257.0%
5Y CAGR-14.6%
10Y CAGR-21.7%

Destiny Meda Tec invested $29K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 257.0% from the prior year.

DSNY Income Statement

Metric Q3'26 Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24
Revenue $1.0M+3.6% $1.0M-19.3% $1.2M+8.6% $1.1M+1.0% $1.1M+11.3% $1.0M-16.9% $1.2M+9.1% $1.1M
Cost of Revenue $166K-1.1% $168K-7.1% $181K-17.4% $219K+35.5% $162K+8.4% $149K-4.4% $156K-3.5% $162K
Gross Profit $873K+4.5% $835K-21.4% $1.1M+14.8% $925K-4.8% $972K+11.8% $870K-18.8% $1.1M+11.2% $962K
R&D Expenses $416K-1.8% $424K-6.8% $455K-9.9% $505K+19.1% $424K-0.9% $428K+3.8% $412K-5.1% $434K
SG&A Expenses $343K-41.7% $588K+249.5% $168K-28.7% $236K+14.6% $206K-47.8% $395K+160.9% $151K-18.2% $185K
Operating Income -$224K+60.7% -$570K-824.5% $79K+120.3% -$387K-400.9% -$77K+75.0% -$309K-381.2% $110K+171.8% -$153K
Interest Expense N/A N/A N/A N/A N/A N/A N/A N/A
Income Tax $0 $0 $0 $0 $0 $0 $0 $0
Net Income -$213K+62.3% -$566K-777.0% $84K+121.9% -$382K-427.9% -$72K+76.1% -$302K-355.7% $118K+183.1% -$142K
EPS (Diluted) $-0.02+66.7% $-0.06-700.0% $0.01 N/A $-0.01+66.7% $-0.03-400.0% $0.01 N/A

DSNY Balance Sheet

Metric Q3'26 Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24
Total Assets $2.4M-8.5% $2.7M-9.8% $3.0M-0.1% $3.0M-8.9% $3.3M+0.5% $3.2M-10.7% $3.6M-1.6% $3.7M
Current Assets $2.1M-3.1% $2.2M-6.5% $2.3M+6.9% $2.2M-0.5% $2.2M+3.1% $2.1M-12.3% $2.4M+2.4% $2.4M
Cash & Equivalents $1.4M+21.4% $1.2M-15.5% $1.4M+21.9% $1.1M-11.4% $1.3M+3.7% $1.2M-20.3% $1.5M+3.0% $1.5M
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable $588K-36.6% $928K+4.3% $890K+3.1% $863K+17.2% $737K+1.3% $727K+0.6% $723K+6.1% $681K
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $741K+1.3% $732K+47.3% $497K-8.7% $544K+36.8% $398K-9.0% $437K-2.2% $447K-14.5% $523K
Current Liabilities $741K+1.3% $732K+47.3% $497K-8.7% $544K+36.8% $398K-9.0% $437K-2.2% $447K-14.5% $523K
Long-Term Debt N/A N/A N/A N/A N/A N/A N/A N/A
Total Equity $1.7M-12.1% $1.9M-21.3% $2.5M+1.9% $2.4M-15.2% $2.9M+2.0% $2.8M-11.9% $3.2M+0.5% $3.2M
Retained Earnings -$6.5M-3.4% -$6.3M-9.9% -$5.7M+1.4% -$5.8M-7.0% -$5.4M-1.3% -$5.4M-6.0% -$5.1M+2.3% -$5.2M

DSNY Cash Flow Statement

Metric Q3'26 Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24
Operating Cash Flow $271K+226.6% -$214K-171.6% $299K+504.9% -$74K-180.8% $91K+153.7% -$170K-178.1% $218K+57.5% $138K
Capital Expenditures $9K+149.5% $4K+1062.2% $325+59.3% $204-96.8% $6K-65.2% $18K+321.2% $4K+105.0% -$87K
Free Cash Flow $261K+220.1% -$218K-172.9% $298K+503.3% -$74K-187.1% $85K+145.1% -$188K-188.2% $213K+315.8% $51K
Investing Cash Flow -$11K+18.5% -$13K+57.0% -$30K-43.7% -$21K+76.9% -$91K+28.2% -$126K-30.4% -$97K-57.8% -$61K
Financing Cash Flow $0 $0 $0 $0 $0 $0 $0 $0
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A $0 $0 $0 $0 $0

DSNY Financial Ratios

Metric Q3'26 Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24
Gross Margin 84.0%+0.8pp 83.2%-2.2pp 85.4%+4.6pp 80.8%-4.9pp 85.7%+0.4pp 85.4%-1.9pp 87.3%+1.7pp 85.6%
Operating Margin -21.6%+35.3pp -56.9%-63.2pp 6.3%+40.1pp -33.8%-27.0pp -6.8%+23.5pp -30.3%-39.2pp 8.9%+22.5pp -13.6%
Net Margin -20.5%+35.9pp -56.5%-63.2pp 6.7%+40.1pp -33.3%-27.0pp -6.4%+23.3pp -29.6%-39.3pp 9.6%+22.3pp -12.7%
Return on Equity -12.5%+16.6pp -29.1%-32.5pp 3.4%+19.1pp -15.8%-13.2pp -2.5%+8.3pp -10.8%-14.5pp 3.7%+8.2pp -4.5%
Return on Assets -8.7%+12.5pp -21.2%-24.0pp 2.8%+15.7pp -12.9%-10.6pp -2.2%+7.1pp -9.3%-12.6pp 3.3%+7.1pp -3.9%
Current Ratio 2.85-0.1 2.98-1.7 4.69+0.7 4.00-1.5 5.50+0.6 4.86-0.6 5.42+0.9 4.52
Debt-to-Equity 0.43+0.1 0.38+0.2 0.20-0.0 0.22+0.1 0.14-0.0 0.16+0.0 0.14-0.0 0.17
FCF Margin 25.1%+46.8pp -21.7%-45.7pp 24.0%+30.4pp -6.5%-14.0pp 7.5%+26.0pp -18.5%-35.9pp 17.4%+12.8pp 4.6%

Similar Companies

Frequently Asked Questions

Destiny Meda Tec (DSNY) reported $4.5M in total revenue for fiscal year 2025. This represents a 2.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Destiny Meda Tec (DSNY) revenue grew by 2.3% year-over-year, from $4.4M to $4.5M in fiscal year 2025.

No, Destiny Meda Tec (DSNY) reported a net income of -$638K in fiscal year 2025, with a net profit margin of -14.1%.

Destiny Meda Tec (DSNY) reported diluted earnings per share of $-0.07 for fiscal year 2025. This represents a -800.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Destiny Meda Tec (DSNY) had EBITDA of $171K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Destiny Meda Tec (DSNY) had a gross margin of 84.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Destiny Meda Tec (DSNY) had an operating margin of -14.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Destiny Meda Tec (DSNY) had a net profit margin of -14.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Destiny Meda Tec (DSNY) has a return on equity of -26.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Destiny Meda Tec (DSNY) generated $36K in free cash flow during fiscal year 2025. This represents a -91.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Destiny Meda Tec (DSNY) generated $65K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Destiny Meda Tec (DSNY) had $3.0M in total assets as of fiscal year 2025, including both current and long-term assets.

Destiny Meda Tec (DSNY) invested $29K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Destiny Meda Tec (DSNY) invested $1.8M in research and development during fiscal year 2025.

Destiny Meda Tec (DSNY) had 10M shares outstanding as of fiscal year 2025.

Destiny Meda Tec (DSNY) had a current ratio of 4.00 as of fiscal year 2025, which is generally considered healthy.

Destiny Meda Tec (DSNY) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Destiny Meda Tec (DSNY) had a return on assets of -21.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Destiny Meda Tec (DSNY) has an Altman Z-Score of 6.13, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Destiny Meda Tec (DSNY) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Destiny Meda Tec (DSNY) has an earnings quality ratio of -0.10x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top